This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Dotan, N Articles by Dukler, A Search for Related Content PubMed PubMed Citation Articles by Dotan, N Articles by Dukler, A Social Bookmarking                         What's this?

Anti-Glycan Antibodies as Biomarkers for Diagnosis and Prognosis

Glycominds Ltd, Lod, Israel, nirdo{at}glycominds.com

RT Altstock

Glycominds Ltd, Lod, Israel

M Schwarz

Glycominds Ltd, Lod, Israel

A Dukler

Glycominds Ltd, Lod, Israel

Glycans (sugars or carbohydrates) are predominant surface components of cells such as erythrocytes, immune cells and microorganisms. As such, they give rise to high levels of anti-glycan antibodies of all classes. Antibodies to certain defined mono, di and oligosaccharides that are common in bacterial, fungal and parasite cells exist in human sera and can be profiled using glycan arrays. The use of glycan arrays for systematic screening of blood samples from multiple sclerosis (MS) and Crohn’s disease (CD) patients in versus to blood samples from control groups, have lead to the discovery of a few anti glycan antibodies biomarkers enabling diagnosis and prognosis in MS and CD patients. Anti-Glc(1,4)Glc() IgM antibodies were found to be specific for MS patients, enabling differentiation between MS patients and patients with other neurological diseases, with 54% sensitivity and 85% specificity. Anti-Glc(1,4)Glc() IgM were found to be predictive for the conversion of patients in first acute neurological event to clinically defined MS. Anti-laminaribioside (ALCA), anti-mannobioside (AMCA) and anti-chitobioside (ACCA) antibodies were found to be specific for CD. The combined use of these antibodies enables improved diagnosis of CD versus ulcerative colitis and other gastrointestinal diseases, as well as stratification of CD patients with a more complicated disease and high risk for surgery. Anti-glycan antibodies profiling (AGAP) is a new and promising approach for development of biomarkers for diagnosis and prognosis.

Key Words: antibodies • Crohn’s disease • diagnosis • glycan-array • multiple sclerosis • prognosis

Lupus, Vol. 15, No. 7, 442-450 (2006)
DOI: 10.1191/0961203306lu2331oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H Dai, Z Li, Y Zhang, P Lv, and X. Gao Elevated levels of serum antibodies against Saccharomyces cerevisiae mannan in patients with systemic lupus erythematosus Lupus, October 1, 2009; 18(12): 1087 - 1090. [Abstract] [PDF]

				C.-C. Wang, Y.-L. Huang, C.-T. Ren, C.-W. Lin, J.-T. Hung, J.-C. Yu, A. L. Yu, C.-Y. Wu, and C.-H. Wong Glycan microarray of Globo H and related structures for quantitative analysis of breast cancer PNAS, August 19, 2008; 105(33): 11661 - 11666. [Abstract] [Full Text] [PDF]